Clearmind Medicine reported Q2 2024 financial results with a net loss of $908,217, compared to $2.07M in Q2 2023. The company ended the quarter with $8.3M cash and working capital of $4.49M, strengthened by a $2.4M registered direct offering in January 2024.The company achieved significant operational milestones, including FDA Type A meeting completion for CMND-100 AUD treatment, Israeli Ministry of Health approval for Phase I/IIa clinical trials, and multiple strategic patent agreements. Notable developments include licensing deals with Hebrew University for PTSD treatment compounds and advancement in alcohol substitute beverage program.Research and development expenses remained stable at $322,956 compared to $317,572 in Q2 2023, while general and administrative expenses decreased to $980,549 from $1.34M. The company's financial position was further enhanced by positive changes in warrant liability valuation and investment gains, contributing to reduced quarterly losses.

Clearmind Medicine reported Q2 2024 financial results with a net loss of $908,217, compared to $2.07M in Q2 2023. The company ended the quarter with $8.3M cash and working capital of $4.49M, strengthened by a $2.4M registered direct offering in January 2024.The company achieved significant operational milestones, including FDA Type A meeting completion for CMND-100 AUD treatment, Israeli Ministry of Health approval for Phase I/IIa clinical trials, and multiple strategic patent agreements. Notable developments include licensing deals with Hebrew University for PTSD treatment compounds and advancement in alcohol substitute beverage program.Research and development expenses remained stable at $322,956 compared to $317,572 in Q2 2023, while general and administrative expenses decreased to $980,549 from $1.34M. The company's financial position was further enhanced by positive changes in warrant liability valuation and investment gains, contributing to reduced quarterly losses.